

Appl. No. 09/489,667

Art Unit 1656

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application. Please cancel claims 77-80 without prejudice.

Listing of Claims

Claims 1-68 (Cancelled).

Claim 69 (Previously presented): An agent for treating pain comprising a modified botulinum neurotoxin comprising a botulinum neurotoxin H<sub>N</sub>, a botulinum neurotoxin L chain, and no functional H<sub>C</sub> domain the modified botulinum neurotoxin being covalently coupled to substance P so that the modified botulinum neurotoxin no longer binds to botulinum neurotoxin receptors at a neuromuscular junction with the same affinity as the native botulinum neurotoxin.

Claim 70 (Cancelled).

Claim 71 (Previously presented): The agent of claim 69 wherein the botulinum neurotoxin is a botulinum toxin selected from the group consisting of serotype A, serotype B, serotype C<sub>1</sub>, serotype D, serotype E, serotype F and serotype G.

Claim 72 (Previously presented): The agent of claim 69 wherein the botulinum neurotoxin is botulinum toxin serotype A.

Claim 73 (Previously presented): The agent of claim 69 wherein the agent is a fusion protein.

Claim 74 (Cancelled).

Claim 75 (Previously presented): The agent of claim 69, wherein the L chain is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C<sub>1</sub>, serotype D, serotype E, serotype F and serotype G.

Appl. No. 09/489,667

Art Unit 1656

Claim 76 (Previously presented): The agent of claim 69, wherein the H<sub>N</sub> is obtained from a botulinum toxin selected from the group consisting of botulinum toxin serotype A, serotype B, serotype C<sub>1</sub>, serotype D, serotype E, serotype F and serotype G.

Claims 77-80 (Cancelled).